Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Finding/Expansion Study of HLX55, A Monoclonal Antibody Targeting Tyrosine-Protein Kinase MET (C-MET) in Patients With Advanced Solide Tumors Refactory to Standard Therapy

NCT04169178 is registered in ClinicalTrials.gov with Henlix, Inc as lead sponsor.

NCT NCT04169178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04169178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Finding/Expansion Study of HLX55, A Monoclonal Antibody Targeting Tyrosine-Protein Kinase MET (C-MET) in Patients With Advanced Solide Tumors Refactory to Standard Therapy
Lead sponsor
Henlix, Inc
Phase
Phase 1
Overall status
Unknown status
Start date
March 3, 2020
Completion date
December 31, 2022
Enrollment
98 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult